A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT05444322 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2022-07-11
Summary
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.
Conditions
- Mantle Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
Interventions
- DRUG
-
RD14-01 cell infusion
Autologous CAR T cells
Sponsors & Collaborators
-
He Huang
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-05
- Primary Completion
- 2024-07-10
- Completion
- 2025-07-10
Countries
- China
Study Locations
More Related Trials
-
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826 ·Status: RECRUITING
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327 ·Status: RECRUITING
-
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
NCT03367143 ·Status: UNKNOWN ·Phase: PHASE2
-
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
NCT00001271 ·Status: COMPLETED ·Phase: PHASE1
-
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
NCT05690191 ·Status: ENROLLING_BY_INVITATION
-
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948 ·Status: UNKNOWN ·Phase: NA
-
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221 ·Status: RECRUITING ·Phase: PHASE2
-
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
NCT04620655 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
NCT05392257 ·Status: UNKNOWN ·Phase: PHASE2
-
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07159906 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
NCT06045585 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT04164368 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
NCT04544059 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690 ·Status: RECRUITING ·Phase: PHASE1
-
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT01466868 ·Status: TERMINATED ·Phase: PHASE2
-
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
NCT05907447 ·Status: UNKNOWN
-
A Retrospective Study on Extranodal DLBCL
NCT06549361 ·Status: COMPLETED
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT01741792 ·Status: COMPLETED ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2